What a shock....

One can only hope they are all like minded and greedy and hang around too long to help lift this stock to where it should be on positive Phase 3 results- double digits.

Swing

Nobody has contributed more to this board than Brentie.

This place is getting bizarre.

Swing

The guy doing most of the technical talking is Bob. I have not heard him before but he appeared to have a handle on the data.

I find it interesting that this was a topline data analysis yet most of the questions were from the assistants of the assigned analysts. The only name I recognized was Simon from Cowen.

The goal of non-inferiority was met in both trials. Without a major in depth analysis of the data how does one separate the impact of Afrezza from the other drugs taken in the studies?

I think we should let them absorb the studies and then decide whether or not the drug will perform as expected.

Swing

http://www.foxbusiness.com/industries/2013/08/14/mannkind-diabetes-drug-tops-expectations-in-study-shares-soar/

That is a great trick. I will have to remember that one.

Congrats Wellsbro.

Swing

First blush it appears type 2 results are better than type 1. If A1c is the standard type 2 results are superior to existing therapy. Very nice.

Bridge to MedTone was successful as desired.

Results look good. I hope the partner cadidates see this as I do!

Swing